Mereo BioPharma shares are trading higher after the company and Ultragenyx Pharmaceutical announced 14-month results from the Phase 2 portion of the ongoing Phase 2/3 Orbit study.
Portfolio Pulse from Benzinga Newsdesk
Mereo BioPharma shares are trading higher following the announcement of positive 14-month results from the Phase 2 portion of the ongoing Phase 2/3 Orbit study, in collaboration with Ultragenyx Pharmaceutical.
June 12, 2024 | 12:57 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Mereo BioPharma shares are trading higher due to positive 14-month results from the Phase 2 portion of the Orbit study, conducted in collaboration with Ultragenyx Pharmaceutical.
The positive results from the Phase 2 portion of the Orbit study are likely to boost investor confidence in Mereo BioPharma, leading to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Ultragenyx Pharmaceutical, collaborating with Mereo BioPharma, announced positive 14-month results from the Phase 2 portion of the Orbit study, which could positively impact its stock price.
The collaboration with Mereo BioPharma and the positive results from the Phase 2 Orbit study are likely to enhance investor sentiment towards Ultragenyx Pharmaceutical, potentially leading to a short-term increase in its stock price.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80